Cancer
Merck’s cancer drug sees first ever early access nod
March 11, 2015Sales and Marketing Cancer, ICR, Merck, eams, early access, keytruda, melanoma, oncology, pembrolizumab
Merck’s skin cancer drug Keytruda has become the first drug to be approved through the new Early Access to Medicines …
Fixing what’s broken: why companies must prioritise innovation in drug development
March 9, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, ICR, The Institute of Cancer Research, innovation, oncology, paul workman
The global system for discovering new cancer drugs is broken. It is failing to turn dramatic scientific advances into enough …
Novartis secures first US biosimilar product
March 6, 2015Research and Development, Sales and Marketing Amgen, Cancer, FDA, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, filgrastim-sndz
Novartis’ generic arm Sandoz has won the race to become the first company to market a biosimilar in the US …
Merck and Eisai partner on cancer therapy trial
March 6, 2015Research and Development, Sales and Marketing Bayer, Cancer, FDA, Halaven, Lenvima, Merck, Stivarga, keytruda, oncology, pd1
Merck and Eisai are teaming up for collaborative trials to test the effects of using combinations of each company’s oncology …
Precision medicine: the future of cancer treatment?
March 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Cancer, Celgene, Precision, melanoma, oncology, underwood
There are plenty of advances in oncology treatments to be excited about – from immunotherapy to cancer vaccines and monoclonal …
Eisai cancer drug performs in sarcoma disease
February 26, 2015Sales and Marketing Cancer, Eisai, Halaven, eribulin, sarcoma, tumour
Eisai’s cancer drug Halaven met its primary endpoint and demonstrated overall survival benefit in two distinct solid tumour types in …
FDA in Novartis cancer drug U-turn
February 24, 2015Research and Development, Sales and Marketing Cancer, FDA, Farydak, Novartis, Revlimid, Velcade, myeloma
The FDA has overturned an earlier advisory committee recommendation and decided to approve Novartis’ blood cancer drug Farydak. In November …
Hormone replacement therapy elevates ovarian cancer risk
February 13, 2015Research and Development, Sales and Marketing Cancer, HRT, Lancet, Oxford, oncology, ovarian
According to a new study women who undergo hormone replacement therapy nearly double their risk of developing ovarian cancer. Findings …
Half of UK population will get cancer
February 4, 2015Research and Development, Sales and Marketing CDF, CRUK, Cancer, Jevtana, Sanofi, cabazitaxel
New figures from Cancer Research UK (CRUK) suggest that one in two people will develop cancer at some point in …
FDA fast-tracks Roche lung cancer drug
February 2, 2015Sales and Marketing Cancer, FDA, MPDL3280A, Roche, bladder, lung, oncology, pdl1
Roche will be celebrating after its investigational cancer drug MPDL3280A has been fast-tracked by the FDA for the second time. …
Novartis earns EMA and FDA nods for Jakavi and Bexsero
January 26, 2015Sales and Marketing Bexsero, Cancer, EU, FDA, Jakavi, Novartis, US, meningitis, ruxolitinib
Novartis has secured the regulatory go-ahead for two of its drugs, after the EMA recommended Jakavi for a rare blood …
UK makes £30m investment in T-Cell cancer therapy
January 22, 2015Research and Development, Sales and Marketing Autolus, Cancer, London, T cell, UK, government, oncology, syncona
The UK is making a £30 million R&D investment into a promising new type of cancer treatment and is to …
Lilly, BMS and Merck unite for cancer trials
January 13, 2015Research and Development, Sales and Marketing BMS, Cancer, Galunisertib, Merck, NSCLC, keytruda, lilly, oncology, opdivo
Lilly will test some of its compounds in combination with rival cancer drugs from Bristol-Myers Squibb and Merck, the companies …
Another NICE no for Dendreon cancer drug
January 13, 2015Sales and Marketing Cancer, Dendreon, FDA, NHS, NICE, Provenge, sipuleucel-T
Dendreon has seen its prostate cancer treatment for people whose disease has spread and who are not yet suitable for …
NHS drops 25 treatments from Cancer Drugs Fund
January 12, 2015Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus
Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
